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SRp20Alternative splicing in mRNA maturation has emerged as a major ﬁeld of study also because of its impli-
cations in various diseases. The SR proteins play an important role in the regulation of this process. Evi-
dence indicates that SRp20 (SFSR3), the smallest member of the SR protein family, is involved in
numerous biological processes. Here we review the state-of-the-art of knowledge about the SR proteins,
in particular SRp20, in terms of its function and misregulation in human diseases including cancer also in
view of its potential as a therapeutic target.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
The alternative splicing (AS) of RNA, a molecular event affecting
the expression of most human genes [1], leads to the production of
multiple isoforms of mature RNA from a single primary transcript.
This event is due to the presence of various splicing sites within
precursor mRNAs (pre-mRNAs). Alternative splicing is regulated
by interactions between cellular splicing factors and RNA se-
quences in the pre-mRNA [2,3], and even very mild changes in
the levels of splicing factors can perturb AS regulation [4].
Alternative splicing causes important temporal and tissue-spe-
ciﬁc changes in the human proteome [2,5]. When a protein exists
as two or more splicing variants, one splicing variant can exert
its function in cooperation with the full-length protein [6], or par-
adoxically exert opposite functions compared to the full-length
counterpart [7]. Splicing reactions in the eukaryotic nucleus are
catalyzed by spliceosomes, which are large enzymatic complexescomposed of small nuclear RNA (snRNA) molecules and of more
than 100 associated auxiliary proteins [8]. Five snRNAs, i.e. U1,
U2, U4, U5 and U6, constitute the major spliceosome and partici-
pate directly in the splicing reaction by interacting with intron
consensus sequences and with each other. An snRNA combined
with a protein forms a small nuclear RiboNucleoProtein (snRNP);
snRNPs assemble on the pre-mRNA to form the spliceosome.
Among the many proteins associated to the spliceosome, there
are two highly conserved protein families: the splicing factors
known as Ser/Arg-rich (SR) proteins and heterogeneous nuclear
RiboNucleoProteins (hnRNPs) [9]. The SR proteins exhibit dual
functionality in pre-mRNA constitutive and alternative splicing.
In fact their primary constitutive function is exerted at the level
of splice-site selection. They interact with exonic splicing enhancer
sequences (ESEs) thereby forming a barrier that prevents exon
skipping, thus ensuring the correct 50 to 30 linear order of exons
in spliced mRNA. In addition, SR proteins regulate the selection
of alternative splice sites (different from canonical sites), thus pro-
moting the inclusion of alternative exons. Moreover, SR proteins
antagonize the activity of hnRNPs, which are bound to exonic splic-
ing silencers (ESSs), at the level of AS regulation [10]. Here we re-
view the state-of-the-art of knowledge about the SR proteins, in
particular SRp20, in terms of its function and misregulation in hu-
man diseases including cancer.
2. The SR protein family
The ﬁrst evidence of the splicing factors function of SR proteins
dates back to the early 1990s [11], whereas the name ‘SR protein’
stems from the recognition of proteins with an RS domain by a
Fig. 1. SR proteins domain structure. Gene symbols and protein names (in
parenthesis) are reported followed by the schematic representation of the domain
structures of the known members of SR family. The SR proteins have one or two N-
terminal RNA recognition motifs (RRMs) and one C terminal RS domain. The RRM
motif identiﬁes and binds speciﬁc RNA sequences. The RS domain interacts with
other proteins and facilitates recruitment of the spliceosomal components.
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II transcription [12]. SF2/ASF was the ﬁrst SR protein identiﬁed
[13]. Subsequently, others, i.e. SRp20, SRp40, SRp55 and SRp75,
were classiﬁed on the basis of their relative MW on SDS/PAGE
gel [14]. More recently, Manley and Krainer proposed a simple def-
inition of SR proteins and rationalized the nomenclature associated
to these proteins [15]. According to their deﬁnition, an SR protein is
any protein with one or two N-terminal RNA-binding domains
(RBDs; also known as RNA recognition motifs [RRMs]) followed
by a downstream arginine/serine-rich (RS) domain characterized
by consecutive RS or SR repeats. Based on this stringent deﬁnition,
there are 12 SR proteins in humans encoded by twelve genes, des-
ignated serine/arginine-rich Splicing Factors (SRSFs) 1-12; these
are listed in Table 1 and their structural organization is illustrated
in Fig. 1.The N-terminal RRM provides substrate speciﬁcity by
modulating the interactions of SR proteins with short mRNA splic-
ing enhancer sequences [16,17]. The C-terminal RS domain aids
protein–protein interactions, thus simplifying spliceosome recruit-
ment [18,19].
Whether SR proteins exert a speciﬁc or non-speciﬁc function re-
mains to be established. It has been suggested that their role is
non-speciﬁc in mRNA splicing [3,16], whereas other studies sug-
gest that some SR proteins play specialized roles [20,21]. Most of
the serine residues of SR proteins are phosphorylated in the RS do-
main and this affects their function in the spliceosome. Despite evi-
dence that RS domain phosphorylation may control splicing [22],
its role in this process needs further investigation. Differently,
the role of phosphorylation in the entry of SR proteins into the nu-
cleus is well-established. This post-translational mechanism
(PTM), in fact, enhances the interactions between the RS domain
and transportin, i.e. the nuclear import receptor [23,24]. The phos-
phorylation mechanism and the structure of SR protein kinases
have been recently reviewed by Ghosh and Adams [25].
The splicing of pre-mRNA is an essential, precisely regulated
molecular process occurring before mRNA translation that pro-
duces functional mRNA molecules via the speciﬁc removal of in-
trons and ligation of exons. It is a crucial regulatory step in
eukaryotic gene expression [26]. After the discovery that genes
are constituted by introns and exons, the concept that one gene
generates multiple forms of mRNA transcripts gradually becameTable 1
SR protein and gene symbols. For each protein the annotated function is summarized bas
Protein name Gene
symbol
Functi
ASF, SF2, SRp30a SRSF1 Plays
regula
SC35, PR264, SRp30b SRSF2 Necess
depen
the 50-
depen
spliceo
apopto
SRp20 SRSF3 Involv
SRp75 SRSF4 Involv
Tau ex
SRp40, HRS SRSF5 Involv
SRp55, B52 SRSF6 Involv
splicin
9G8 SRSF7 Requir
MAPT
SRp46 SRSF8 AS reg
splicin
other
SRp30c SRSF9 Involv
splicin
TASR1, SRp38, SRrp40 SRSF10 Involv
P54, SRp54 SRSF11 May fu
SRrp35 SRSF12 Seemsplausible [27]. Alternative splicing of pre-mRNA can help to ex-
plain the incongruity between gene content and organism com-
plexity at protein level [28,29].
It is thought that most genes of the human genome undergo
alternative splicing [2,30] and that, on average, a given gene gives
rise to 4 alternatively spliced variants that differ in their sequence
and therefore in the activities of the coded proteins. Four types of
AS events have been described: alternative 50 splice site selection,
alternative 30 splice site selection, cassette-exon inclusion or skip-
ping, and intron retention [29]. For an in-depth account of the role
of SR proteins in constitutive and alternative splicing see the article
by Long and Caceres [3].
While AS plays a signiﬁcant role in normal cellular develop-
ment, changes or defects in this process have also been linked to
human disease, including cancer [31,32]. Consequently, aberrant
mRNAs, splicing factors and other RNA processing factors have be-
come targets for new therapeutic approaches for various human
diseases.ed also on information obtained from the EMBL-EBI database.
on
a role in preventing exon skipping, ensuring the accuracy of splicing and
ting AS. Isoform ASF-2 and isoform ASF-3 act as splicing repressors.
ary for the splicing of pre-mRNA. Required for formation of the earliest ATP-
dent splicing complex, interacts with spliceosomal components bound to both
and 30-splice sites during spliceosome assembly. It also is required for ATP-
dent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other
somal components. The phosphorylated form (by SRPK2) is required for cellular
sis in response to cisplatin treatment. Exerts transcription corepressor activity.
ed in RNA processing in relation with cellular proliferation and/or maturation.
ed in AS site selection during pre-mRNA splicing. Represses the splicing of MAPT/
on 10.
ed in constitutive splicing, can modulate the selection of AS sites.
ed in constitutive splicing, can modulate the selection of AS sites. Represses the
g of MAPT/Tau exon 10. RNA binding.
ed for pre-mRNA splicing. Can also modulate AS in vitro. Represses the splicing of
/Tau exon 10. RNA binding; zinc ion binding.
ulator, regulates its own expression at the level of RNA processing and the
g of ﬁbronectin and CD45 genes. May act, at least in part, by interaction with
R/S-containing splicing factors. Represses the splicing of MAPT/Tau exon 10.
ed in constitutive splicing, can modulate the selection of AS sites. Represses the
g of MAPT/Tau exon 10.
ed in constitutive and regulated RNA splicing.
nction in pre-mRNA splicing.
to antagonize SR proteins in pre-mRNA splicing regulation.
Fig. 2. SRp20 features. (A) The protein has an RNA recognition motif (RRM) in the N-terminus and an arginine/serine-rich domain (RS) at the C-terminus. In green are the
amino acids of the RRM domain and in red those of the RS domain. (B) Genes known to be regulated by SRp20 are listed with their biological function and implication in
diseases.
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SRp20 (also called SRSF3) is the smallest member of the highly
conserved SR-rich splicing factor family and is constituted by one
RRM at the N-terminus and one RS domain at the C-terminus.
The protein is composed of 164 amino acids, about half of which
belong to the RS domain (Fig. 2A); its molecular weight is about
19 kDa and it is extensively phosphorylated on serine residues in
the RS domain. SRp20 regulates the splicing of numerous genes
[33–43]. It affects AS by interacting with RNA cis-elements in a
concentration- and cell differentiation-dependent fashion [44]. A
summary of genes regulated by SRp20 is shown in Fig. 2B. At the
end of the 90s, Jumaa and Nielsen showed that SRp20 regulates
the AS of its own mRNA, thereby providing the ﬁrst demonstration
of auto-regulatory activity of an SR protein [33–35]. In fact, SRp20
promotes the inclusion of exon 4 of its own mRNA and reduces the
expression of the full-length SRSF3 protein [35].
Besides its regulation of RNA splicing, SRp20 is also involved in
other important cellular functions. It has been implicated in pro-
tein translation [45], termination of transcription [46] and insulin
signaling [47]. In a proteomic analysis of insulin signaling in hu-
man hematopoietic cells, SRp20 and CLIC1 were identiﬁed as novel
downstream effectors of insulin-dependent signals. Importantly,
the insulin-induced reduction in SRp20 enhances insulin-depen-
dent accumulation of cyclin D3 [47].
A recent study demonstrated that SRp20 (SRSF3) and SF2/ASF
(SRSF1) associate with chromatin before and after, but not during,
mitosis [48]; this interaction implies that these proteins could be
involved in the regulation of chromatin structure and function
and thus may play a role in cell cycle control. SRp20 is involved
in mRNA polyadenylation [49], which implicates it in pre-mRNA
processing and, more in general, in terminal exon recognition.
SRp20 also acts as a shuttle in the TAP-dependent mRNA export
from nucleus to cytoplasm [50–52]. Its role in embryogenesis
was revealed by a study showing that SRp20-null mouse embryos
did not form blastocytes, and died at morula stage [53].
4. SRp20 in human disease including cancer
The biological relevance of AS is supported by observations
linking aberrant AS to human diseases, including tumorigenesis[32,54–58]. In this context, a variety of SRp20 functions are associ-
ated with their alterations in human or animal diseases. Proteins
SRp20, 9G8 and ASF/SF2 were proposed as activators of the AS of
the adhesion molecule CD44. In fact, the CD44 gene alternative
exon v9 contains a splicing enhancer responsive to these three
SR proteins [36,37].
The human TAU gene, which encodes a protein of 441 amino
acids, contains 16 exons, three of which undergo AS thereby gener-
ating different isoforms of tau proteins. In the search for potential
therapeutic targets for tauopathies, Yu and colleagues studied the
splicing mechanism of TAU and found that SRp20 participates in
the AS of TAU by promoting the exclusion of exon 10 [38]. SRp20
is also involved in the alternative splicing of ﬁbronectin [39], insu-
lin receptor [40], and Rac1 [41]. SRp20 activates the inclusion of
exon 10 of the pyruvate kinase M (PK-M) gene to promote the
expression of the oncogenic PK-M2 isoform, thus fostering aerobic
glycolysis and tumor growth [42]. SRp20 has also been implicated
in the neurodegenerative disorder Alzheimer’s disease. In fact,
SRp20 regulates the splicing of TRKB to generate TrkB-Shc tran-
scripts that are involved in this disorder [43]. Lastly, SRp20 con-
trols the early-to-late switch in human papillomavirus by
regulating the gene expression of the virus via interaction with
A/C-rich RNA elements [44].
Since mutations in oncogenes and tumor suppressors can lead
to cancer, it is hardly surprising that also mutations at exon–intron
junctions that affect splicing can cause cancer. The expression of
the splicing factor SRp20 is triggered by oncogenic signaling path-
ways such as the Wnt signaling pathway that drives the formation
of several cancers [37,41,59]. Importantly, SRp20 protein levels
correlate with the extent of b-catenin/TCF4 signaling in the colo-
rectal cancer cell lines SW480, HT29, and DLD1, which are widely
used to study this signaling [37]. Moreover, our studies conﬁrmed
a direct cause-effect relationship between Wnt pathway activation
and increased SRp20 expression, and demonstrated that SRp20
expression was higher in colon cancer stem-like cells than in
non-cancer stem-like cells [59]. Furthermore, we found that
SRp20 silencing slowed down cell proliferation, thereby implicat-
ing SRp20 in the tumorigenicity of cancer stem-like cells isolated
from CaCo-2 cells [59, for cancer stem cells studies see also 60,61].
Jia and colleagues discovered the role of SRp20 in proliferation
[62]. They demonstrated that it promotes the G2/M transition by
4 C. Corbo et al. / Biochemical and Biophysical Research Communications 436 (2013) 1–5affecting the expression of the cell cycle regulators FoxM1, Cdc25B
and PLK1. Therefore, SRp20 is critical for the control of the G2/M
phase transition and for the prevention of cell apoptosis. Moreover,
when looking at SRp20 function in the splicing of human papillo-
mavirus (HPV) RNA, Jia and collaborators found a remarkable in-
crease in SRp20 expression in cervical cancer tissues [62]. This
phenomenon is not limited to HPV-induced cancers; SRp20 is over-
expressed also in lung, breast, stomach, skin, bladder, colon, liver,
thyroid, and kidney tumor tissue, and in B-cell lymphoma cells
[62]. SRp20 over-expression is required for ovarian cancer cell
growth and maintenance of transformation properties [63,64]. In
fact, ovarian cancer cells with reduced SRp20 expression grow
slowly, do not grow in an anchorage-independent fashion, undergo
apoptosis and are less tumorigenic [63]. SF2/ASF, SRp20 and SC35
were also found to be speciﬁcally up-regulated in a model of cervi-
cal tumor progression and are also over-expressed in high-grade
cervical lesions, which indicates that they may have oncogenic
functions. Given the changes associated with SR proteins, the latter
may be used as biomarkers for diagnosis of cervical tumor progres-
sion [65].
A very recent study demonstrated that SRp20 regulates cellular
senescence [66]. The process of cellular senescence is the ability of
cells to enter a state of irreversible proliferation arrest; importantly
the mechanisms underlying cellular senescence are involved in
protection against cancer. SRp20 regulates cellular senescence
through alternative splicing of TP53, thereby generating p53b
[66]. In detail, SRp20 downregulation induces the generation of
p53b and is an endogenous mechanism to promote cellular senes-
cence [66], which suggests that SRp20 is involved in tumorigenesis
and that it is a direct regulator of p53.
ASF/SF2 and SRp20 are two antagonistic splicing factors that
regulate Rac1b expression in colorectal tumor cells. Rac1 is a mem-
ber of the Rho family of small GTPases that are involved in signal-
ing pathways that control proliferation, actin-dependent cell
motility, invasiveness of tumor cells as well as gene transcription.
The AS variant Rac1b is over-expressed in a subset of colorectal tu-
mors and is required to sustain tumor cell viability and subsequent
tumor progression [41].
Acute myeloid leukemia (AML) also known as acute myeloge-
nous leukemia is the most common type of blood cancer affecting
adults, and its incidence increases with age. There is growing evi-
dence of a link between AML and aberrant alternative splicing of
pre-mRNA, which may result from aberrant expression of splicing
factors, these being the real mediators of splicing reactions. Com-
pared to healthy controls, the expression of splicing factors SRSF1,
SRSF3 and SRSF4 mRNAs is signiﬁcantly decreased in newly diag-
nosed AML patients [67]. This aberrant expression may be related
to the abnormal expression of oncogenes in AML and could be use-
ful for the early diagnosis, prognosis, and therapy of this disorder.
The AS of kruppel-like factor 6 (KLF6) tumor suppressor is a key
event in hepatocellular carcinoma (HCC). In fact, SRp20 contributes
to cell proliferation in physiologic liver growth and HCC through
SRSF1-mediated AS of KLF6 [68]. Moreover, SRp20 loss in liver
leads to aberrant splicing of genes involved in glucose/lipid metab-
olism (HNF1a, ERN1, HMGCS1, DHCR7 and SCAP) thus impairing the
morphological and functional differentiation of hepatocytes [69].5. Concluding remarks
The ﬁnding that most human pre-mRNA transcripts are alterna-
tively spliced prompted efforts to understand the signiﬁcance of AS
in various biological processes. In this scenario, there is growing
interest in the molecular components that orchestrate the regula-
tion of AS. The splicing factor SRp20 has long been studied as a reg-
ulator of pre-mRNAs AS, but only in recent years has SRp20 beenlinked to cancer. The data summarized in this review support the
link between SRp20 and cancer and the existence of a role of
SRp20 in the general splicing machinery in tumorigenesis. Under-
standing and identifying the molecular mechanisms governing
SRp20-dependent signaling will have an impact on the clinical
management of cancer patients and on the identiﬁcation of the
most promising molecular targets for treatment.
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